Jon P. Stonehouse
President, Chief Executive Officer
Jon P. Stonehouse, a pharmaceutical executive for more than 20 years, has strong commercialization, financial transaction, business development and management expertise. He most recently served as Senior Vice President of Corporate Development at Merck KGaA with responsibility for global licensing and business development, corporate mergers and acquisitions, corporate strategic planning and alliance management. Among his accomplishments, he was responsible for leading the effort to develop a strategy for Merck that significantly changed the company. This culminated with the acquisition of Serono, S.A., the largest biotechnology company in Europe at the time of the agreement.
Thomas R. Staab, II
Senior Vice President, Chief Financial Officer
Tom Staab joined the BioCryst Leadership Team in July 2011, bringing his skill and experience regarding the financial stewardship of publically-traded companies, development and commercialization of pharmaceutical products and raising capital through strategic partnerships, equity and debt financings. Mr. Staab most recently served as Executive Vice President, CFO and Treasurer of Inspire Pharmaceuticals from May 2003 through its $430 million acquisition by Merck & Co., Inc. in May 2011. Prior to joining Inspire, he held the senior financial positions of Acting CFO and Treasurer at Triangle Pharmaceuticals, Inc. through its $480 million acquisition by Gilead Sciences, Inc. Additionally, Mr. Staab spent eight years working for PricewaterhouseCoopers LLP providing audit and business advisory services to national and multi-national corporations in the biotechnology, pharmaceutical, pulp and paper and communications industries. Tom currently serves on the Executive Committee of the Board of Directors of the North Carolina Biosciences Organization (“NCBIO”) as its Chairman and previously served as the Chairman of its Audit Committee.
He is a Certified Public Accountant and received a B.S. in Business Administration and a Masters of Accounting from the University of North Carolina at Chapel Hill.
William P. Sheridan, MB BS
Senior Vice President, Chief Medical Officer
Dr. William Sheridan joined BioCryst in July 2008. Dr. Sheridan is a seasoned biotechnology professional. During a 15-year tenure at Amgen, Dr. Sheridan organized and led the company's U.S. Medical Affairs function, making significant contributions to the successful launch of many compounds, including Aranesp®, Enbrel®, Kineret®, Neulasta® and Sensipar®, and led several product development teams. At Amgen, Dr. Sheridan held titles at the Vice President level in North American Medical Affairs, International Medical Affairs, Global Health Economics and Outcomes Research, U.S. Medical Affairs, and Product Development. He played an integral role in building Amgen's domestic and international medical affairs functions and in forming the health economics and outcomes unit. Dr. Sheridan earned his MB BS degree (M.D. equivalent) at the University of Melbourne in Victoria, Australia. Dr. Sheridan is a board-certified fellow of the Royal Australasian College of Physicians (FRACP), with a sub-specialty in medical oncology, and a Fellow of the American College of Physicians.
Yarlagadda S. Babu, Ph.D.
Senior Vice President, Drug Discovery
Dr. Babu directs a team of structural biologists, medicinal chemists and research biologists and oversees the structure-based drug discovery program at the company. Dr. Babu was BioCryst's first full-time employee having joined the Company in 1988. Prior to joining BioCryst, he served five years on the biochemistry faculty at the University of Alabama at Birmingham (UAB). He obtained his Ph.D. from the Indian Institute of Science, Bangalore and spent three years in the Laboratory of Molecular Biophysics at the University of Oxford, UK before joining UAB. He has over 70 scientific publications in peer-reviewed journals, and a number of issued and pending patents to his credit.
Vice President, General Counsel & Corporate Secretary
Alane Barnes joined BioCryst in 2006 and is responsible for all legal affairs of the company including but not limited to all contract negotiations, SEC compliance, corporate governance, IP strategy and management, licensing transactions, government contract management and dispute resolution. She graduated magna cum laude from Cumberland School of Law in 1997 and is a member of Curia Honoris, scholar of merit. Currently, she serves on the Board of the Biotechnology Association of Alabama and has served as a mentor for Alabama Launchpad, a competition created to fuel the development of companies in Alabama. Mrs. Barnes has also spoken at national conferences regarding the pharmaceutical business and at other women’s success conferences. She is a 2010 graduate of MOMENTUM, an organization geared toward building leadership in women.
Elliott Berger, Ph.D.
Senior Vice President, Regulatory Affairs
Dr. Elliott Berger joined BioCryst in August 2007. Dr. Berger has more than 30 years of experience in the pharmaceutical industry, including over 25 years devoted to management of regulatory affairs supporting new drug and biologic development. Prior to joining BioCryst, he was Vice President, Regulatory Affairs and Quality Assurance, Head of Global Regulatory Strategy at EMD Pharmaceuticals, the North American subsidiary of Merck KGaA. As part of the EMD start-up team, Dr. Berger built and managed the EMD Regulatory Affairs, Clinical Quality Assurance and Drug Safety Groups, as well as the Global Regulatory Strategy Group. At EMD, Dr. Berger submitted and managed over 10 Investigational New Drug Applications (NDA) in areas of oncology, diabetes, cardiovascular disease and neurology. Dr. Berger also prepared and submitted the NDA for Cyanokit ® which was approved within 6 months of submission to the FDA. Prior to EMD, Dr. Berger was a member of the Senior Executive Team at Astra Pharmaceuticals, most recently serving as Vice President, Regulatory Affairs.
Dr. Berger received both his Ph.D. and M.S. degrees in Biometrics as well as his B.A. degree in Mathematics from Temple University.
Senior Vice President & Chief Commercial Officer
Ms. Lynne Powell joined BioCryst Pharmaceuticals as Senior Vice President and Chief Commercial Officer in January 2015. In this role, Lynne’s primary responsibility will be to formulate BioCryst’s global commercial strategy and to build the global organization that launches our oral kallikrein inhibitors for the prophylactic treatment of hereditary angioedema. Ms. Powell brings 24 years of industry experience to BioCryst. Most recently she served as Senior Vice President of North American Commercial Operations at CSL Behring. In this role, she was accountable for the financial performance and general management of CSL Behring’s commercial activities within the U.S. and Canada. Throughout her 17 year career at CSL Behring, Ms. Powell assumed increasing responsibilities within the R&D, and commercial functions of the organization. She has significant global experience gained as Vice President, Global Commercial Development and Head of Business Development & European Marketing. Ms. Powell launched five products globally for rare diseases, including hereditary angioedema (HAE). Prior to CSL, she held positions of increasing responsibility within GlaxoWellcome’s commercial strategy and clinical research organizations.
Dr. Carol Ohmstede
Vice President of Project Management
Dr. Carol Ohmstede joined BioCryst Pharmaceuticals in July 2016 as Vice President of Project Management. Dr. Ohmstede has approximately 30 years of experience in the pharmaceutical industry including 18 years focused on project & program management of new molecular entities from Research through Commercialization. Prior to joining BioCryst, she was Senior Director of Project and Portfolio Management – Liver Diseases at Gilead Sciences where she directed a team of project managers focused on the development of new drugs against Hepatitis C, Hepatitis B and nonalcoholic steatohepatitis (NASH). As part of the Liver Diseases team at Gilead, she was the program manager for the development and launch of Sovaldi® and Harvoni® for the treatment of chronic Hepatitis C. Previously, Dr. Ohmstede was at Trimeris, where she served in roles of increasing responsibility in project and portfolio management of the HIV Fusion Inhibitor program resulting in the development and launch of Fuzeon® in partnership with Hoffmann-La Roche. At BioCryst, Dr. Ohmstede will oversee the project management of the HAE portfolio and coordinate the management of the overall BioCryst project portfolio.
Vice President, Human Resources
Mr. Robert Stoner joined BioCryst in January 2008. Mr. Stoner brings more than 28 years of progressive Human Resources experience to BioCryst, having worked in a diverse group of industries during his career. Prior to joining BioCryst, Mr. Stoner served as Senior Vice President Human Resources at Smith Breeden Associates, Inc. an institutional financial management company in Chapel Hill, North Carolina. Prior to joining Smith Breeden Associates, Mr. Stoner held the position of Vice President Human Resources at EMD Pharmaceuticals, the North American subsidiary of Merck KGaA. At EMD, Mr. Stoner was responsible for human resource functions for multiple locations and was a member of the Global HR Team, coordinating and directing global HR initiatives within North America.
Mr. Stoner participated in and graduated from the Merck University Executive Management Program, attending Northwestern University, Kellogg School of Management, Hong Kong University of Science and Technology and INSEAD in Paris. Mr. Stoner received his B.S. in Business Administration from Southern Illinois University.